Direct detection of myoglobin in whole blood using a disposable amperometric immunosensor

Biosensing Platforms for Cardiac Biomarker Detection

Myocardial infarction (MI) is a cardiovascular disease that occurs when there is an elevated demand for myocardial oxygen as a result of the rupture or erosion of atherosclerotic plaques. Globally, the mortality rates associated with MI are steadily on the rise. Traditional diagnostic biomarkers employed in clinical settings for MI diagnosis have various drawbacks, prompting researchers to investigate fast, precise, and highly sensitive biosensor platforms and technologies. Biosensors are analytical devices that combine biological elements with physicochemical transducers to detect and quantify specific compounds or analytes. These devices play a crucial role in various fields including healthcare, environmental monitoring, food safety, and biotechnology. Biosensors developed for the detection of cardiac biomarkers are typically electrochemical, mass, and optical biosensors. Nanomaterials have emerged as revolutionary components in the field of biosensing, offering unique properties that significantly enhance the sensitivity and specificity of the detection systems. This review provides a comprehensive overview of the advancements and applications of nanomaterial-based biosensing systems. Beginning with an exploration of the fundamental principles governing nanomaterials, we delve into their diverse properties, including but not limited to electrical, optical, magnetic, and thermal characteristics. The integration of these nanomaterials as transducers in biosensors has paved the way for unprecedented developments in analytical techniques. Moreover, the principles and types of biosensors and their applications in cardiovascular disease diagnosis are explained in detail. The current biosensors for cardiac biomarker detection are also discussed, with an elaboration of the pros and cons of existing platforms and concluding with future perspectives.

Electrochemical cardiovascular platforms: Current state of the art and beyond

Cardiovascular diseases (CVD) remain the leading cause of death within industrialized nations as well as an increasing cause of mortality and morbidity in many developing countries. Smoking, alcohol consumption and increased level of blood cholesterol are the main CVD risk factors. Other factors, such as the prevalence of overweight/obesity and diabetes, have increased considerably in recent decades and are indirect causes of CVD. Among CVDs, the acute coronary syndrome (ACS) represents the most common cause of emergency hospital admission. Since the prognosis of ACS is directly associated with timely initiation of revascularization, missed, misdiagnosis or late diagnosis have unfavorable medical implications. Early ACS diagnosis can reduce complications and risk of recurrence, finally decreasing the economic burden posed on the health care system as a whole. To decrease the risk of ACS and related CVDs and to reduce associated costs to healthcare systems, a fast management of patients with chest pain has become crucial and urgent. Despite great efforts, biochemical diagnostic approaches of CVDs remain difficult and controversial medical challenges as cardiac biomarkers should be rapidly released into the blood at the time of ischemia and persistent for a sufficient length of time to allow diagnostics, with tests that should be rapid, easy to perform and relatively inexpensive. Early biomarker assessments have involved testing for the total enzyme activity of aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and creatine kinase (CK), which cardiac troponins being the main accepted biomarkers for diagnosing myocardial injury and acute myocardial infarction (AMI). To allow rapid diagnosis, it is necessary to replace the traditional biochemical assays by cardiac biosensor platforms. Among the numerous of possibilities existing today, electrochemical biosensors are important players as they have many of the required characteristics for point-of-care tests. Electrochemical based cardiac biosensors are highly adapted for monitoring the onset and progress of cardiovascular diseases in a fast and accurate manner, while being cheap and scalable devices. This review outlines the state of the art in the development of cardiac electrochemical sensors for the detection of different cardiac biomarkers ranging from troponin to BNP, N-terminal proBNP, and others.

Recent progress on the sensitive detection of cardiovascular disease markers by electrochemical-based biosensors

Cardiovascular disease is the most reason for deaths in all over the world. Hence, biomarkers of cardiovascular diseases are very crucial for diagnosis and management process. Biomarker detection demand is opened the important way in biosensor development field. Rapid, cheap, portable, precise, selective and sensitive biomarker sensing devices are needed at this point to detect and predict disease. A cardiac biomarker can be orderable as C-reactive protein, troponin I or T, myoglobin, tumor necrosis factor alpha, interleukin-6, interleukin-1, lipoprotein-associated phospholipase, low-density lipoprotein and myeloperoxidase. They are used for prediction of cardiovascular diseases. There are many methods for early diagnosis of cardiovascular diseases, but these have long time process and expensive devices. In recent studies, different biosensors have been developed to remove the problems in this field. Electrochemical devices and developed biosensors have many superiorities than others such as low cost, mobile, reliable, repeatable, need a little amount of solution. In this review, recent studies were presented as details for cardiovascular disease biomarkers detection using electrochemical methods.

From mercury to nanosensors: Past, present and the future perspective of electrochemistry in pharmaceutical and biomedical analysis

Polarography was the first developed automated method of voltage-controlled electrolysis with dropping mercury electrode (DME). Then, hanging mercury drop and static mercury drop electrodes were added as an alternative indicator electrode. In this way, polarography turned formally into voltammetry with mercury electrodes in the electroreduction way. Solid electrodes such as noble metal and carbon based electrodes can be used for the investigation of the compounds for both oxidation and reduction directions, which is called voltammetry. The voltammetric and polarographic techniques are more sensitive, reproducible, and easily used electroanalytical methods that can be alternative to more frequently used separation and spectrometric methods. Furthermore, in some cases there is a relationship between voltammetry and pharmaceutical samples, and the knowledge of the mechanism of their electrode reactions can give a useful clue in elucidation of the mechanism of their interaction with living cells. The voltammetric and polarographic analysis of drugs in pharmaceutical preparations are by far the most common use of electrochemistry for analytical pharmaceutical problems. Recent trends and challenges in the electrochemical methods for the detection of DNA hybridization and pathogens are available. Low cost, small sample requirement and possibility of miniaturization justifies their increasing development.

Microstructural and electrochemical impedance characterization of bio-functionalized ultrafine ZnS nanocrystals-reduced graphene oxide hybrid for immunosensor applications

We report a mercaptopropionic acid capped ZnS nanocrystals decorated reduced graphene oxide (RGO) hybrid film on a silane modified indium-tin-oxide glass plate, as a bioelectrode for the quantitative detection of human cardiac myoglobin (Ag-cMb). The ZnS nanocrystals were anchored over electrochemically reduced GO sheets through a cross linker, 1-pyrenemethylamine hydrochloride, by carbodiimide reaction and have been characterized by scanning electron microscopy, transmission electron microscopy and energy dispersive X-ray spectroscopy. The transmission electron microscopic characterization of the ZnS-RGO hybrid shows the uniform distribution of ultra-fine nanoparticles of ZnS in nano-sheets of GO throughout the material. The protein antibody, Ab-cMb, was covalently linked to ZnS-RGO nanocomposite hybrid for the fabrication of the bioelectrode. A detailed electrochemical immunosensing study has been carried out on the bioelectrode towards the detection of target Ag-cMb. The optimal fitted equivalent circuit model that matches the impedance response has been studied to delineate the biocompatibility, sensitivity and selectivity of the bioelectrode. The bioelectrode exhibited a linear electrochemical impedance response to Ag-cMb in a range of 10 ng to 1 μg mL(-1) in PBS (pH 7.4) with a sensitivity of 177.56 Ω cm(2) per decade. The combined synergistic effects of the high surface-to-volume ratio of ZnS(MPA) nanocrystals and conducting RGO has provided a dominant charge transfer characteristic (R(et)) at the lower frequency region of <10 Hz showing a good biocompatibility and enhanced impedance sensitivity towards target Ag-cMb. The impedance response sensitivity of the ZnS-RGO hybrid bioelectrode towards Ag-cMb has been found to be about 2.5 fold higher than that of a bare RGO modified bioelectrode.

Employing denaturation for rapid electrochemical detection of myoglobin using TiO2 nanotubes

An alternative antibody-free strategy for the rapid electrochemical detection of cardiac myoglobin has been demonstrated here using hydrothermally synthesized TiO₂ nanotubes (Ti-NT). The denaturant induced unfolding of myoglobin led to easy access of the deeply buried electroactive heme center and thus the efficient reversible electron transfer from protein to electrode surface. The sensing performance of the Ti-NT modified electrodes were compared vis a vis commercially available titania and GCEs. The tubular morphology of the Ti-NT led to facile transfer of electrons to the electrode surface, which eventually provided a linear current response (obtained from cyclic voltammetry) over a wide range of Mb concentration. The sensitivity of the Ti-NT based sensor was remarkable and was equal to 18 μA mg^-1 ml (detection limit = 50 nM). This coupled with the rapid analysis time of a few tens of minutes (compared to a few days for ELISA) demonstrates its potential usefulness for the early detection of acute myocardial infarction (AMI).

Lab-on-a-chip based immunosensor principles and technologies for the detection of cardiac biomarkers: a review

This review examines the current state of the art lab-on-a-chip and microfluidic based biosensor technologies used in the detection of cardiac biomarkers. The determination and quantification of blood based, cardiac biomarkers are crucial in the triage and management of a range of cardiac related conditions, where time delay has a major impact on short and longer-term outcomes of a patient. The design and manufacturing of biomarker detection systems are multi-disciplinary in nature and require researchers to have knowledge of both life sciences and engineering for the full potential of this field to be realised. This review will therefore provide a comprehensive overview of chip based immunosensing technology as applied to cardiac biomarker detection, while discussing the potential suitability and limitations of each configuration for incorporation within a clinical diagnostics device suitable for point-of-care applications.

Modeling of dielectrophoretic transport of myoglobin molecules in microchannels

Myoglobin is one of the premature identifying cardiac markers, whose concentration increases from 90 pgml or less to over 250 ngml in the blood serum of human beings after minor heart attack. Separation, detection, and quantification of myoglobin play a vital role in revealing the cardiac arrest in advance, which is the challenging part of ongoing research. In the present work, one of the electrokinetic approaches, i.e., dielectrophoresis (DEP), is chosen to separate the myoglobin. A mathematical model is developed for simulating dielectrophoretic behavior of a myoglobin molecule in a microchannel to provide a theoretical basis for the above application. This model is based on the introduction of a dielectrophoretic force and a dielectric myoglobin model. A dielectric myoglobin model is developed by approximating the shape of the myoglobin molecule as sphere, oblate, and prolate spheroids. A generalized theoretical expression for the dielectrophoretic force acting on respective shapes of the molecule is derived. The microchannel considered for analysis has an array of parallel rectangular electrodes at the bottom surface. The potential and electric field distributions are calculated using Green's theorem method and finite element method. These results also compared to the Fourier series method, closed form solutions by Morgan et al. [J. Phys. D: Appl. Phys. 34, 1553 (2001)] and Chang et al. [J. Phys. D: Appl. Phys. 36, 3073 (2003)]. It is observed that both Green's theorem based analytical solution and finite element based numerical solution for proposed model are closely matched for electric field and square electric field gradients. The crossover frequency is obtained as 40 MHz for given properties of myoglobin and for all approximated shapes of myoglobin molecule. The effect of conductivity of medium and myoglobin on the crossover frequency is also demonstrated. Further, the effect of hydration layer on the crossover frequency of myoglobin molecules is also presented. Both positive and negative DEP effects on myoglobin molecules are obtained by switching the frequency of applied electric field. The effect of different shapes of myoglobin on DEP force is studied and no significant effect on DEP force is observed. Finally, repulsion of myoglobin molecules from the electrode plane at 1 KHz frequency and 10 V applied voltage is observed. These results provide the ability of applying DEP force for manipulating nanosized biomolecules such as myoglobin.

Electrochemical nanobiosensor for express diagnosis of acute myocardial infarction in undiluted plasma

The myocardial infarction biomarker myoglobin was quantified at the biological level in undiluted plasma using developed electrochemical nanosensors with immobilized anti-myoglobin. Method for cardiac myoglobin detection is based on direct electron transfer between Fe(III)-heme and electrode surface modified with gold nanoparticles/didodecyldimethylammonium bromide (DDAB/Au) and antibodies. The procedure of myoglobin detection was optimized (pH, incubation times and characteristics of electrodes) to express determination of the marker in serum or plasma. Plasma of healthy donors and patients with acute myocardial infarction (AMI) was analyzed using electrochemical immunosensors and RAMP immunoassay. Square wave voltammetry cathodic peak of cardiac myoglobin reduction was found to be proportional to myoglobin quantity in plasma as determined by RAMP. The method proposed does not require signal enhancement or amplification; nor does it require labeled secondary antibodies. Immunosensor has a detection limit of 10 ng/ml (0.56 nM) and a broad range of working concentrations (10-1780 ng/ml; 0.56-100 nM). The whole procedure takes 30 min and can be used for express diagnosis of acute myocardial infarction.

State of the art and recent advances in immunoanalytical systems

This article is an overview the state of the art and the recent developments in immunosensors. Homogeneous immunosensors, heterogeneous immunosensors, integrated immunosensors and biochip format immunosensors are presented, based on optical, electrochemical, magnetic or mechanical detection/transduction systems.

Recent advances in analytical chemistry--a material approach

Advancements of materials research have profound direct impacts on developments in analytical chemistry and may hold the key to improvement of existing or new techniques at present times and near future. Applications of materials in analytical chemistry are reviewed, with focus on sensors, separations and extraction techniques. This review aims to survey examples of interesting works carried out in the last five years over a broad spectrum of materials classified as hybrids, nanomaterials and biomolecular materials.

Determination of myoglobin based on its enzymatic activity by stopped-flow spectrophotometry

A new method has been developed for the determination of myoglobin (Mb) based on its enzymatic activity for the oxidation of o-phenylenediamine (OPDA) with hydrogen peroxide. Stopped-flow spectrophotometry was used to study the kinetic behavior of the oxidation reaction. The catalytic activity of Mb was compared to other three kinds of catalyst. The time dependent absorbance of the reaction product, 2,3-diamimophenazine (DAPN), at a wavelength of 426 nm was recorded. The initial reaction rate obtained at 40 degrees C was found to be proportional to the concentration of Mb in the range of 1.0 x 10(-6) to 4.0 x 10(-9)mol L(-1). The detection limit of Mb was found to be 9.93 x 10(-10)mol L(-1). The relative standard deviations were within 5% for the determination of different concentrations of Mb. Excess of bovine serum albumin (BSA), Ca(II), Mg(II), Cu(II), glucose, caffeine, lactose and uric acid did not interfere.